Verano Holdings (VRNO) Operating Income (2021 - 2026)
Verano Holdings' (VRNO) quarterly Operating Income came in at $13.1 million in Q1 2026, down 12.68% year-on-year from $15.0 million in Q1 2025, and up 108.31% on a QoQ basis from -$157.6 million in Q4 2025.
Verano Holdings (VRNO) Operating Income (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Operating Income data on file, last reported at $13.1 million in Q1 2026.
- On a quarterly basis, Operating Income fell 12.68% year-over-year to $13.1 million in Q1 2026; TTM through Mar 2026 was -$109.0 million, a 55.48% increase from a year earlier, with the FY2025 full-year figure at -$107.1 million, up 54.85% from the prior year.
- Operating Income for Q1 2026 stood at $13.1 million, up from -$157.6 million in the prior quarter.
- Over the last five years, Operating Income for VRNO reached as high as $40.3 million in Q3 2023 and fell as low as -$303.9 million in Q4 2024.
- Historically, Operating Income has averaged -$24.5 million across 5 years, with a median of $15.0 million in 2025.
- Across the five-year window, Operating Income surged 1962.39% in 2023 and slumped 1441.77% in 2024, its largest moves.
- Year by year, Operating Income stood at -$207.0 million in 2022, then soared by 90.48% to -$19.7 million in 2023, then slumped by 1441.77% to -$303.9 million in 2024, then surged by 48.14% to -$157.6 million in 2025, then jumped by 108.31% to $13.1 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were $13.1 million in Q1 2026, -$157.6 million in Q4 2025, and $9.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.10 Mn |
| Dec 31, 2025 | -157.58 Mn |
| Sep 30, 2025 | 9.28 Mn |
| Jun 30, 2025 | 26.21 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | -303.88 Mn |
| Sep 30, 2024 | 16.77 Mn |
| Jun 30, 2024 | 27.27 Mn |
| Mar 31, 2024 | 22.67 Mn |
| Dec 31, 2023 | -19.71 Mn |
| Sep 30, 2023 | 40.29 Mn |
| Jun 30, 2023 | 30.43 Mn |
| Mar 31, 2023 | 33.78 Mn |
| Dec 31, 2022 | -206.98 Mn |
| Sep 30, 2022 | 37.08 Mn |
| Jun 30, 2022 | -2.29 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 29.43 Mn |
| Sep 30, 2021 | 23.01 Mn |
| Jun 30, 2021 | -158,000.00 |